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Abstract 
A Breast Cancer Outcomes model was developed at the ONCOTYROL research center to evaluate personalized test-
treatment strategies in Austria. The goal was to evaluate the cost-effectiveness of a new 21-gene assay (ODX) when 
used in conjunction with the Adjuvant! Online (AO) decision aid to support personalized decisions about use of adju-
vant chemotherapy in early-stage breast cancer patients in Austria. We applied a validated discrete-event-simulation 
model to a hypothetical cohort of 50 years old women over a lifetime horizon. The test-treatment strategies of interest 
were defined using three-letter acronyms. The first (second, third) letter indicates whether patients with a low (inter-
mediate, high) risk according to AO were tested using ODX (Y yes, N no). The main outcomes were life-years gained, 
quality-adjusted life-years (QALYs), costs and cost effectiveness. Robustness of the results was tested in sensitivity 
analyses. Results were compared to a Canadian analysis conducted by the Toronto Health Economics and Technol-
ogy Assessment Collaborative (THETA). Five of eight strategies were dominated (i.e., more costly and less effective: 
NNY, NYN, YNN, YNY, YYN). The base-case analysis shows that YYY (ODX provided to all patients) is the most effec-
tive strategy and is cost effective with an incremental cost-effectiveness ratio of 15,700 EUR per QALY gained. These 
results are sensitive to changes in the probabilities of distant recurrence, age and costs of chemotherapy. The results 
of the base-case analysis were comparable to the THETA results. Based on our analyses, using ODX in addition to AO is 
effective and cost effective in all women in Austria. The development of future genetic tests may require alternative or 
additional test-treatment strategies to be evaluated.
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Background
Breast cancer accounts for 28  % of all malignancies 
in Austrian women (Statistik Austria 2012). Based on 
current projections, seven of every 100 Austrian girls 
born in 2009 will develop breast cancer by the age of 
75 (Statistik Austria 2012). Aside from a small per-
centage of familial breast cancer syndromes, risk fac-
tors include age, early menarche, late menopause, 
and obesity [Arbeitsgemeinschaft für gynäkologische 
Onkologie (AGO) der Österreichischen Gesellschaft 
für Gynäkologie und Geburtshilfe (OEGGG) 2012]. 
Currently, various treatment strategies are available 
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[Leitlinienprogramm Onkologie (OL) 2012]. When 
possible, surgical resection offers a potential cure. 
Adjuvant treatment after surgery with radiation and/
or systemic therapy (including chemotherapy and/or 
hormonal therapy) depends on the surgical approach, 
stage of the disease, hormone receptor status [e.g., 
estrogen receptor (ER) and progesterone receptor 
(PR) status], postmenopausal status, HER2/neu status, 
pathologic findings and co-morbidities. In part due to 
the length of treatment and potential severe and lethal 
side effects, the use of adjuvant chemotherapy has been 
heavily investigated in terms of its impact on risk of 
recurrence and overall survival.
In particular for women with lymph node negative, 
ER positive early-stage breast cancer, the decision 
about whether to treat with adjuvant chemotherapy is 
complex and uncertain. Adjuvant chemotherapy can be 
beneficial for women at higher risk of a distant recur-
rence, but can cause more harm for low risk patients. 
There are several prognostic tests available that can 
identify women who are most likely to benefit from 
adjuvant therapy. For example, Adjuvant! Online (AO) 
is a free, web-based decision aid designed to help 
patients and clinicians understand individual risk, the 
impact of systemic therapy. AO estimates breast can-
cer-specific mortality and recurrence after surgery for 
various chemotherapy and hormonal treatment options 
based on the patient’s age, comorbidities, estrogen 
receptor status, tumor size, tumor grade and number 
of positive lymph nodes (Adjuvant! Online Inc 2012). 
MammaPrint® and OncotypeDX® are gene expression 
assays that quantify the risk of distant disease recur-
rence (Agency for Healthcare Research and Quality 
2012).
We evaluated the benefit-harm balance and cost 
effectiveness of the 21-gene assay OncotypeDX® 
[Genomic Health Inc., Redwood City, CA, USA 
(ODX)] because it was considered potentially useful 
for adjuvant chemotherapy decision-making by 84 % of 
the experts at the 2011 St. Gallen Consensus Confer-
ence (Gnant et  al. 2011). In 2013, the European Soci-
ety for Oncology (ESMO) concurred that in cases of 
uncertainty regarding adjuvant chemotherapy (after 
consideration of other tests), gene expression, assays 
such as MammaPrint® or OncotypeDX® may be used. 
The analytical and clinical test validity of this assay 
convinced the majority of the IMPACT 2012 Working 
Group members in its clinical use (Azim et  al. 2013). 
However, the 21-gene assay is not currently offered in 
Austria.
Several studies have evaluated the impact of ODX on 
treatment decisions as compared to common clinical 
and pathological criteria such as the National Com-
prehensive Cancer Network (NCCN) guidelines, the 
NSABP B-20 study or Adjuvant! Online (AO) (Adju-
vant! Online Inc 2012). Most studies have identified an 
impact on decisions and changes in use of chemother-
apy in up to 50 % of all patients (Asad et al. 2008; Henry 
et al. 2009; Klang et al. 2010; Lo et al. 2010; Oratz et al. 
2007, 2011). For the most part, recommendations have 
changed from chemotherapy plus hormonal therapy 
to hormonal therapy alone in patients with ER-posi-
tive and LN-negative breast cancer (Henry et al. 2009; 
Lo et  al. 2010; Liang et  al. 2007). In these patients, 
chemotherapy and its associated adverse events may 
be avoided. In addition, increased confidence among 
medical oncologists and decreased patient anxiety were 
reported with the use of ODX (Lo et al. 2010) .
The cost effectiveness of using ODX has been evalu-
ated in several studies (Klang et al. 2010; Hall et al. 2012; 
Kondo et al. 2008, 2011; Lyman et al. 2007; Paulden et al. 
2013; Reed et al. 2009; Tsoi et al. 2010; Ward et al. 2013; 
Yang et al. 2012; Hornberger et al. 2005). However, phy-
sicians may want to consider clinicopathological factors 
(like in AO) along with genomic test results, especially 
when the risk classification with AO is validated and free 
of charge. We found only two studies that considered the 
combination of both tests (Paulden et al. 2013; Reed et al. 
2009). These studies did not cover Austrian treatment 
patterns or costs.
Therefore, the aim of our study was to evaluate the 
effectiveness and the cost effectiveness of ODX when 
it is used or not used in conjunction with the AO score 
to guide decisions about use of adjuvant chemotherapy 
women diagnosed with ER and/or PR positive, HER-2/




We applied a previously published and validated deci-
sion-analytic model to estimate life years (LY) and 
quality-adjusted life years (QALY) (Jahn et  al. 2012a, 
b) (Jahn et al. 2015). In addition, we also estimated the 
number of adverse drug events due to chemotherapy, 
number of patients with a distant recurrence, num-
ber of patients who die from a distant recurrence, 
long term costs as well as incremental cost-effec-
tiveness ratios (ICER) for each of the eight strategies 
being evaluated (see next section). In the base-case 
analysis, a hypothetical cohort of 50-year old women 
diagnosed with ER and/or PR positive, HER-2/neu 
negative, and lymph node negative breast cancer was 
evaluated over their remaining lifetime. The societal 
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perspective in the Austrian health care context was 
adopted. Only direct costs were considered to avoid 
double counting (Gold et al. 1996). For our Oncotyrol 
model, we applied a discrete event simulation model 
(DES) approach using ARENA (version 13.90.00000, 
Rockwell Automation). Our choice was guided by the 
ISPOR-SMDM guidelines that take into account that 
individual patient pathways are determined by multi-
ple characteristics and test results, while considering 
time-dependent functional relationships, and record-
ing of individual patient pathways (Karnon et al. 2012; 
Caro et al. 2012).
Model structures
In this individual-level computer simulation, hypotheti-
cal patients were projected over a lifelong analytic time 
horizon after they had received surgery. The model 
included 4 parts: first, patients were assigned their char-
acteristics and test results (Module 1—risk classification); 
second, chemotherapy was provided if necessary (Mod-
ule 2—chemotherapy); third, the time patients remained 
free from a distant recurrence was considered (Module 
3—recurrence free); and fourth, distant recurrence was 
considered (Module 4—recurrence). Finally, a statisti-
cal module provided a summary of the model outcomes 
(Fig. 1).
In Module 1, we evaluated eight two-test strate-
gies to determine if chemotherapy should be given. 
We assumed that each patient was assigned an indi-
vidualized breast cancer specific mortality (BCSM) 
risk based on the AO assessment. (Adjuvant! Online 
Inc 2012): ‘low’ (BCSM  <  9  %), ‘intermediate’ 
(9  %  ≤  BCSM  <  17  %) or ‘high’ (BCSM  ≥  17  %) risk 
(Bryant 2005). The BCSM risk assigned by AO was 
then used to determine if genomic testing with ODX 
would be pursued. Because genomic testing results in 
additional costs and because it is recommended that 
ODX may be used in conjunction with all clinical and 
pathologic factors in cases where the decision about 
use of chemotherapy is difficult (Azim et  al. 2013; al 
2013), we assume a sequential application (AO first, 
followed by ODX). ODX provides a recurrence risk 
score between 0 and 100, in which ‘low’ is consid-
ered RS  <  18, ‘intermediate’ 18  ≤  RS  <  30 and ‘high’ 
(RS ≥  30) (Paik et  al. 2004). The eight test-treatment 
strategies evaluated are described using three letters: 
NNN, YYY, NNY, NYN, YNN, YYN, YNY and NYY. 
The first letter indicates whether patients with a low 
risk according to AO were tested using the 21-gene 
assay (Y-yes; N–no), the second and the third letters 
provide this information for AO intermediate and 
high risk patients, respectively (e.g., NYN means that 
only patients with an AO intermediate risk are tested 
with the 21-gene assay). Adjuvant chemotherapy was 
then provided according to the results of both tests 
(see Table  1). Patients in the model move to Module 
2 (adjuvant chemotherapy) or directly to Module 3 
(follow-up) as appropriate. In Module 2, chemother-
apy and associated adverse drug events (neutropenia, 
fever, infections, pain, nausea, gastrointestinal com-
plications) were modeled. After the administration of 
chemotherapy, patients were considered recurrence-
free and move to Module 3. In Module 3, each patient 
was followed until death from other causes or dis-
tant recurrence. Within the first 3  years, patients are 
assumed to have quarterly visits, thereafter biannually 
and after 5 years, annually. The regular visits consist of 
a clinical examination and mammography. Within the 
first 5  years, all patients receive aromatase inhibitors. 
In the case of a distant recurrence, the associated diag-
nostic work-up and treatment are modeled in Module 
4. At any point in time, patients may die from other 
causes. In addition, patients receiving chemotherapy 
may die from adverse events and patients with meta-
static disease may die from breast cancer. Within the 
simulation, information on patients’ remaining lifetime 
and quality-adjusted lifetime, adverse drug events, and 
costs are accumulated and final outcomes are com-
puted at the end of their simulated lifetime.
The model structure and a comprehensive model vali-
dation process are described in more detail elsewhere 
(Jahn et al. 2012a, b, 2015).
Model parameters
Clinical parameters
Table  1 provides an overview of model parameters and 
sources.
The proportion of patients assigned to each of the 
12 risk groups according to AO and ODX was based on 
a retrospective study (Paulden et al. 2013). The provision 
of chemotherapy within the twelve risk groups was based 
on a prospective study in a North American population 
(Lo et  al. 2010) and adapted based on Austrian expert 
opinion (Medical University Innsbruck 2012) for the AO 
low risk groups. Time to recurrence for different risk 
classes was derived from Paulden et  al. (2013). Because 
there are no published prospective studies that report 
distant recurrences conditional on 21-gene assay or AO 
risk, Paulden et al. (2013) used findings from a retrospec-
tive analysis based on a subset of the NSABP B-14 study 
(Bryant 2005) and from a subset of the NSABP B-20 
study (Paik et al. 2006).
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Fatal toxicity of chemotherapy includes 0.1 % of patients 
that will subsequently develop acute myeloid leukemia.
For patients with distant recurrence, we assumed that 
the probability of death due to breast cancer was identical 
in all patients regardless of the ER/PR status or patients′ 
personal cancer history. Median survival for these 
patients was estimated as 25.8 months (Medical Univer-
sity Innsbruck 2012). We assumed that the time to recur-
rence in recurrence-free patients and the time to death in 
patients with recurrence was exponentially distributed.
All-cause mortality was extrapolated using life tables 
from Statistics Austria (2012).
Cost data
The price of the 21-gene assay was adapted from the 
manufacturer’s suggested retail price for Austria (Jahn, 
Personnel email-communication with manufacturer 
2012, unpublished). Direct costs for chemotherapy, can-
cer follow-up, and diagnosis and treatment of recurrent 
malignancies were based on internal calculations of the 
Fig. 1 Schematic model structure (ER/PR + : estrogen and/or progesterone receptor positive, LY: life years, QALY: quality adjusted life years, ADE: 
adverse drug event, Int.: intermediate, AO: Adjuvant!Online, ODX: OncotypeDX, N/A: not applied) Source: Jahn et al. (2015). Lessons Learned from a 
Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment. 
Medical Decision Making (published ahead of print). Copyright © 2015 by Society for Medical Decision Making. Reprinted by permission of SAGE 
Publications, Inc.
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Table 1 Model parameter overview
Parameters Values Sources
Proportion of patients assigned to each risk group
 Adjuvant! Online low risk 52.99 % Paulden et al. (2013)
  21-Gene assay low risk 32.34 %
  21-Gene assay int. risk 12.57 %
  21-Gene assay high risk 8.08 %
 Adjuvant! Online int. risk 18.71 %
  21-Gene assay low risk 8.53 %
  21-Gene assay int. risk 3.59 %
  21-Gene assay high risk 6.59 %
 Adjuvant! Online high risk 28.29 %
  21-Gene assay low risk 9.73 %
  21-Gene assay int. risk 6.14 %
  21-Gene assay high risk 12.43 %
Proportion of patients in each risk group provided adjuvant chemotherapya
 Adjuvant! Online low risk 0 % Lo et al. (2010); Medical University Innsbruck (2012)
  21-Gene assay low risk 0 %
  21-Gene assay int. risk 17.62 %
  21-Gene assay high risk 63.44 %
 Adjuvant! Online int. risk 55.06 %
  21-Gene assay low riska 13.73 (T1, base case)/(0 % T2, SA)
  21-Gene assay int. risk 36.56 %
  21-Gene assay high risk 98.61 %
 Adjuvant! Online high risk 57.57 %
  21-Gene assay low risk 13.72 %
  21-Gene assay int. risk 36.65 %
  21-Gene assay high risk 99.73 %
 Risk of hospital visit due to toxicity 17.04 % Tilak Financial Department and Cost Data Report (2012)
Cause of hospital visits due to toxicity
 Neutropenia/fever/infections 53.56 % Medical University Innsbruck (2012)
 Pain & pain management 7.51 %
 Nausea/vomiting/dehydration 6.02 %
 Gastrointestinal tract 5.64 %
10 year risk for distant recurrence without chemotherapy
 Adjuvant! Online low risk 5.39 % Paulden et al. (2013)
  21-Gene assay low risk 2.61 %
  21-Gene assay int. risk 3.84 %
  21-Gene assay high risk 18.91 %
 Adjuvant! Online int. risk 20.36 %
  21-Gene assay low risk 4.24 %
  21-Gene assay int. risk 14.90 %
  21-Gene assay high risk 44.23 %
 Adjuvant! Online high risk 24.12 %
  21-Gene assay low risk 4.24 %
  21-Gene assay int. risk 14.90 %
  21-Gene assay high risk 44.23 %
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Table 1 continued
Parameters Values Sources
10 year risk for distant recurrence with chemotherapy
 Adjuvant! Online low risk 5.68 % Paulden et al. (2013)
  21-Gene assay low risk 4.98 %
  21-Gene assay int. risk 5.62 %
  21-Gene assay high risk 8.58 %
 Adjuvant! Online int. risk 7.35 %
  21-Gene assay low risk 5.79 %
  21-Gene assay int. risk 8.18 %
  21-Gene assay high risk 8.91 %
 Adjuvant! Online high risk 7.68 %
  21-Gene assay low risk 5.79 %
  21-Gene assay int. risk 8.18 %
  21-Gene assay high risk 8.91 %
 Risk of mortality due to toxicity from chemotherapy 0.1 % Medical University Innsbruck (2012)
 Median life expectancy following distant recurrence 
(months)
25.8 Medical University Innsbruck (2012)
 Risk of mortality due to other causes Life table Statistik Austria (2012)
Costs (inflated to 2011 Euros)
 21-Gene assay 3180 Jahn, Personnel email-communication with manufacturer 
(2012, unpublished)
Costs for chemotherapy
 Echocardiography (one time) 28 Tilak Financial Department and Cost Data Report (2012)
 Chest radiography (one time) 23
 Port implantation (one time) 550
 Laboratory test (per cycle of chemotherapy) 46.5
 Blood panel (per week for 6 months) 3.75
 Human resources (per cycle of chemotherapy) 48
 Hospitalization (3 days) 620
 Total additional costs for chemotherapy (6 months) 2,089.5
 Total costs for FEC (Fluorouracil 500 mg/m2, Cyclophospa-
mid 600 mg/m2, Epirubicin 90 mg/m2)
672.16
 Total costs for DOC (Docetaxel 75 mg/m2) 1042.5
 Pegfilgrastim 6 mg 1175.57
 Tropisetron-Hydrochlorid 5 mg 5 pills 85.90
 Total costs for chemotherapy (Additional costs, FEC, DOC, 
Pegfilgrastim, Tropisetron-Hydrochlorid, 6 months)
11,372.96 Derived from Tilak Financial Department and Cost Data 
Report (2012); Medical University Innsbruck (2012)
Follow up costs for the first 5 years after chemo therapy (costs per month/treatment)
 Anastozol 1 mg 73.7 Tilak Financial Department and Cost Data Report (2012)
 Lertozolum 2.5 mg 101.2
 Exemestanum 25 mg 75.87
 Other treatment costs for the first 5 years after chemo 5016.8 Derived from Tilak Financial Department and Cost Data 
Report (2012); Medical University Innsbruck (2012)
 Mammography 32 Tilak Financial Department and Cost Data Report (2012)
 Examination 85.5
 Follow up costs for the first 5 years after chemo per month 21.54 Derived from Tilak Financial Department and Cost Data 
Report (2012); Medical University Innsbruck (2012)
Follow up Costs after the first 5 years after chemo therapy (costs per month/treatment)
 Follow up costs per month 9.79 Derived from Tilak Financial Department and Cost Data 
Report (2012); Medical University Innsbruck (2012)
Costs of diagnosing distant recurrence
 Total costs of diagnosis of distant recurrence 248.5 Derived from Tilak Financial Department and Cost Data 
Report (2012); Medical University Innsbruck (2012)
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financial department of the Tyrolienne Hospital Operat-
ing Company (TILAK) (Tilak Financial Department and 
Cost Data Report 2012) and expert opinion from the 
Innsbruck Medical University (Medical University Inns-
bruck 2012). Drug costs were based on pharmacy hospi-
tal prices.
Costs for chemotherapy included the costs of chemo-
therapeutic agents, other supportive medications such 
as pegfilgrastim and tropisteron, hospitalization, labo-
ratory studies, and human resources. It was assumed 
that all patients receive the current standard of care in 
terms of chemotherapeutic agents. At present, this is 
three cycles of FEC (5-Fluorouracil, Epirubicin, Cyclo-
phosphamid) followed by 3 cycles of DOC (Docetaxel) 
(Hubalek 2010).
All patients also received an aromatase inhibitor 
(anastozol or lertozolum or aromasin) for 5  years. This 
was begun immediately in all cases except in those who 
received chemotherapy, in which case the aromatase 
inhibitor was started following the completion of adju-
vant chemotherapy.
Underlying assumptions regarding the treatment of 
distant recurrence were derived from chart reviews by a 
senior gynecologist at Innsbruck Medical Hospital.
Costs associated with adverse drug events of chemo-
therapy were based on published data (Ontario Case 
Costing Initiative 2011) and adapted according to Aus-
trian experts (Medical University Innsbruck 2012). Treat-
ment of fatal toxicity included treatment of acute myeloid 
leukemia. Cost data were evaluated based on German 
DGHO treatment guidelines (DGHO guidelines 2013). 
Cost were derived from or inflated to Euros 2011. Costs 
and health outcomes were discounted at 5 % (Walter and 
Zehetmayr 2006).
Utility data
Utility weights for the different breast cancer states were 
derived from a recent cross-sectional observational study 
(Lidgren et  al. 2007) using the EQ-5D, a standardized, 
non-disease-specific instrument for describing and valu-
ing health states (while on hormone therapy, while on 




We estimated discounted LYs, QALYs, number of patients 
who experienced adverse drug events, disease recurrence, 
costs, and ICERs (additional costs per QALY gained). For 
the cost-effectiveness results, we excluded dominated strat-
egies. These are strategies that provide fewer QALYs at a 
higher cost. We also excluded strategies due to extended 
dominance. Strategies are extendedly dominated if there is 
a more expensive strategy with a lower ICER. (Cantor 1994).
The cost-effectiveness results are displayed on a cost-
effectiveness plane. The resulting line that connects the 
most efficient strategies is called the efficiency frontier. 
Strategies that lie on the efficiency frontier are relevant 
for decision makers, whereas strategies below the line are 
considered dominated and inefficient.
Finally, incremental cost-effectiveness ratios of strat-
egies on the efficiency frontier are compared to the rel-
evant threshold. In Austria, there is currently no explicit 
cost-effectiveness threshold for the adoption of health 
Table 1 continued
Parameters Values Sources
Costs of treating distant recurrence
 Total costs per 25.8 months 32,015.26 Tilak Financial Department and Cost Data Report (2012)
Treatment of non-fatal chemotherapy toxicity
 Neutropenia/fever/infections 5231.46 Ontario Case Costing Initiative (2011); Medical University 
Innsbruck (2012) Pain management 3270.66
 Nausea/vomiting/dehydration 3173.45
 Gastrointestinal tract 5169.31
 Treatment of fatal toxicity 36,260 Walter (2012)
Utility weights
 First year following diagnosis (while on hormone 
therapy)
0.744 Lidgren et al. (2007)
 First year following diagnosis (while on chemotherapy) 0.620
 Second and following years prior to distant recurrence 0.779
 Following distant recurrence 0.685
 Dead 0
a Parameter values differ for the two treatment strategies T1 (base case)/T2 (sensitivity analysis)
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technologies. Thresholds applied in other countries vary 
and are rarely cancer specific (Schwarzer et  al. 2015). 
For example, in Canada the chair of the Ontario expert 
review committee suggested an oncology-specific ceil-
ing threshold value of C$75,000 (this is equivalent to 
$US65,914 for 2009). NICE provided a general threshold 
in 2012 of £18,317/QALY (US$25,435) that can be altered 
based on other factors.
Sensitivity analyses
We performed several one-way sensitivity analyses 
to account for parameter uncertainty (“second-order 
uncertainty”). This relates to the fact that the probabili-
ties applied in the model are themselves uncertain: for 
example, values from clinical studies have confidence 
intervals. (Briggs et  al. 2012a, b). The results are dis-
played in a modified tornado diagram that shows the 
variation in outcomes according to one parameter on 
a horizontal bar. Along the vertical axis, all relevant 
parameters are shown. The outcome of the base-case 
is indicated by a vertical line cutting through all hori-
zontal bars. The longest bar reflects the most uncertain 
parameter (Briggs et  al. 2012, b). We applied a content 
specific order of the parameters (bars), that is: age (40; 
50; 70), discount rate (0; 2.5 %; 5 %), cost of chemother-
apy (±10 %), cost of ODX test set (±10 %), utilities (95 % 
confidence intervals assuming beta distribution), distri-
bution of AO risk groups (±20  %) and probabilities of 
distant recurrence (95  % confidence interval, assuming 
beta distribution).
In addition, the results of our analysis from an Austrian 
perspective were compared to a Canadian cost-effective-
ness study conducted by the Toronto Health Economics 
and Technology Assessment (THETA) Collaborative. 
(Paulden et al. 2013). The THETA group developed and 
applied a probabilistic Markov model (state-transition 
cohort model).
For our analysis, 100,000 patients were simulated per 




The results of the base-case analysis for Austria are dis-
played in Table 2. When compared to AO alone (NNN), 
using ODX in intermediate and high risk patients (NYY) 
increased discounted life years and QALYs by 2.8  % 
(NNN: 14.33 LY, 11.08 QALY; NYY: 14.73 LY, 11.40 
QALY). When using ODX in all patients (YYY) life years 
and QALYs increased by 4.1  % (YYY: 14.92 LY, 11.54 
QALY). However, costs also increased by 3.9  % (NNN: 
13,180 EUR, NYY: 13,710 EUR) to 13.9  % (YYY: 15,930 
EUR).
The base-case analysis shows that YYY (ODX provided 
to all patients) is the most effective strategy and is cost 
effective with an ICER of 15,700 EUR per QALY gained 
when compared to other technologies in health and 
medicine. Strategies NNN and NYY are also on the cost-
effectiveness frontier but they are less effective. Five of 
eight strategies were dominated (i.e., more costly and less 
effective: NNY, NYN, YNN, YNY, YYN).
In Table 3, further information on the benefits and harms 
of the evaluated strategies are displayed. Here we see that, 
for example, the strategy NYY leads to the fewest people 
(0.0301 %) suffering from adverse drug events (ADE). Pro-
viding ODX to all patients leads to a higher number of ADE 
(0.0396  %) compared to NYY but fewer patients develop 
recurrence (NYY: 0.2051 %; YYY 0.1722 %).
Sensitivity analysis
In the sensitivity analysis, different adjuvant chemother-
apy treatment patterns were considered (Fig.  2). It was 
assumed that chemotherapy was provided to 13.73 % of 
patients who had an intermediate risk according to AO 
Table 2 Cost-effectiveness of ODX in the Austrian setting
a NA not applicable since NNN is the first comparator
b D dominated strategies discounted
Strategy Base‑case analysis ∆Total costs × 1000€ ICER (€/QALY)
LYs QALYs ∆QALYs Total costs ×1000€
1-NNN 14.33 11.08 – 13.18 – NAa
3-NYN 14.46 11.18 – 13.36 – Db
2-NNY 14.60 11.29 – 13.58 – D
4-NYY 14.73 11.40 0.32 13.71 0.53 1628.35
5-YNN 14.46 11.17 – 15.48 – D
7-YYN 14.64 11.31 – 15.61 – D
6-YNY 14.76 11.41 – 15.81 – D
8-YYY 14.92 11.54 0.14 15.93 2.22 15,727.78
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and a low risk according to ODX in the base case (T1). 
In the sensitivity analysis that assumed none of AO inter-
mediate/ODX low patients received chemotherapy (T2), 
the strategies NYY and YYY remained cost-effective with 
an ICER comparable to the base case. In addition, the 
strategy NYN (ICER: 501 EUR/QALY) was cost-effective 
(Additional file 1: Table S1).
Further sensitivity analyses found that strategies NYY 
and YYY remain on the cost-effectiveness frontier with 
thresholds below 5,300 EUR/QALY (NYY) and 47,000 
EUR/QALY (YYY) (Tornado diagram Fig.  3; Additional 
file  2: Figure S1). Strategy YYY was dominated only 
when the probability of distant recurrence was increased 
(upper end of the 95 % confidence interval). The strategy 
NYN was cost effective when we tested the lower and 
upper bound of the confidence interval for distant recur-
rence, 10 % variation in costs, 20 % variation in the AO 
risk group distribution, a lower discount rate (2.5 %) and 
younger patient population (40 years). The strategy NNY 
was cost effective when we tested the upper bound of the 
confidence interval for distant recurrence for patients 
who did not receive chemotherapy. All other test-treat-
ment strategies remained dominated (Additional file  1: 
Table S1).
The comparison of the Austrian base-case analysis and 
the Canadian analysis by THETA is displayed in Fig. 4.
Discussion
We developed a decision-analytic model for the evalua-
tion of the 21-gene assay in women diagnosed with ER 
and/or PR positive, HER-2/neu negative, and lymph node 
negative breast cancer in Austria. The model is flexible 
and can be adapted and applied to other countries and 
health care contexts.
We have demonstrated that the 21-gene assay is a cost-
effective tool for determining which ER/PR+, Her2/neu 
negative early breast cancer patients receive adjuvant 
chemotherapy when used in two scenarios in the Aus-
trian context; first when used only in patients with a high 
or intermediate AO risk score (strategy NYY) (ICER 
Table 3 Additional model outcomes
a Per 100,000 patients







1-NNN 0.0325 0.2677 26,078
2-NNY 0.0318 0.22828 22,186
3-NYN 0.0308 0.24287 23,636
4-NYY 0.0301 0.20509 19,863
5-YNN 0.0422 0.23507 22,905
6-YNY 0.0417 0.19817 19,290
7-YYN 0.0412 0.21193 20,593





































   
Lifeme costs in each strategy (thousands €)  
Oncotyrol T1 (Austria)
Oncotyrol T2 (Austria)
1,628€ per QALY 
15,728€ per QALY 
1,434 € per QALY 
501 € per QALY 
16,395 € per QALY 
Fig. 2 Cost-effectiveness frontier for Austrian test-treatment strategy T1 (base case) and T2 (sensitivity analysis). Sensitivity analysis: risk group AO 
intermediate/ODX low receive no chemotherapy whereas in the base case 13.73 % would receive chemotherapy, treatment for other risk groups as 
in base case); ICER – Incremental Cost-Effectiveness Ratios for the not dominated strategies that are on the frontier (ICER = additional costs/addi-
tional QALYs for the next most expensive strategy)
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1600 EUR/QALY) and second, when used in all patients 
independent of the AO risk score (Strategy YYY) (ICER 
15,700 EUR/QALY). All other strategies that include test-
ing of low risk AO (YNN, YNY, YYN) are dominated and 
should not be considered as cost-effective options. With 
respect to the sensitivity analysis, it seems that the strat-
egy where only AO intermediate risk patients are tested 
(NYN) could also be a relevant option.
The modeling study shows that the 21-gene assay is 
cost effective for all AO risk groups. However, there is 
always the trade-off that the 21-gene assay uses resources 
that could be used elsewhere. Providing the genetic 
test to patients with AO intermediate or high risk only 
would be a cost-effective alternative that uses fewer total 
resources. However, drivers for the use of the 21-gene 
assay for AO low risk patients may include disagreements 
Fig. 3 Tornado diagram for the scenario YYY. prob. probability, dist. rec. distant recurrence, follow. following, diag. diagnosis; Parameter range: (A) 
(40; 50; 70) (DR) (0; 2.5 %; 5 %), (C1) and (C2) ± 10 %, (U1) - (U3) 95 % confidence intervals assuming beta distribution, (P1) ± 20 %, (P2) and (P3) 








































   
Lifeme costs in each strategy (thousands €)  
Oncotyrol (Austria)
THETA (Canada)
1,628€ per QALY 
15,728€ per QALY 17,281€ per QALY 
1,945€ per QALY 
856€ per QALY 
Fig. 4 Cost-effectiveness frontier comparison between Austrian and Canadian settings (incl. ICER values)
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between physicians and patients, uncertainty and anxi-
ety in patients as well as individual health considerations. 
The time for the genetic testing seems acceptable. The 
recurrence score is evaluated from a tissue sample sent to 
Genomic Health within 10–14 calendar days.
The 21-gene assay estimate can differ from the Adju-
vant! recurrence estimate for several reasons. The 
21-gene assay recurrence estimate is for distant recur-
rence only (risk of metastatic disease) while AO estimates 
the risk for all causes of recurrence (local, regional, con-
tralateral breast cancer and distant recurrence). Because 
of this difference in the endpoint definition, Adjuvant!’s 
estimates of “risk of recurrence” are usually higher than 
those of the ODX test. However, the most appropri-
ate comparisons are between the risk of breast cancer 
mortality as estimated by AO and the risk of distant 
recurrence as given by the ODX test, though an exact 
comparison is not possible (Sinn et al. 2013).
Several studies examined the cost effectiveness of ODX 
driven treatment (Klang et  al. 2010; Kondo et  al. 2008, 
2011; Lyman et al. 2007; Paulden et al. 2013; Reed et al. 
2009; Tsoi et al. 2010; Ward et al. 2013; Yang et al. 2012; 
Hornberger et al. 2005). In the majority of these studies, 
ODX was found to be superior to conventional risk clas-
sification methods (Klang et al. 2010; Kondo et al. 2008, 
2011; Lyman et  al. 2007; Tsoi et  al. 2010; Hornberger 
et al. 2005). Hall et al. (2012) stated that ODX could be 
very cost effective for the NHS in the UK, but there is 
uncertainty in the evidence to support this claim. The 
Health Technology Assessment by Ward et  al. (2013) 
reported that “compared with current clinical practice, 
OncotypeDX had a 12.4 % (all women) and 91.6 % (Not-
tingham Prognostic Index >3.4) probability of being con-
sidered cost effective when using a threshold of £20,000 
per QALY gained respectively”. Yang et  al. (2012) com-
pared two different gene expression profiles and con-
cluded that Mammaprint to be even more effective and 
less costly than ODX. However, these analyses did not 
consider the provision of ODX conditional upon AO risk 
and therefore implicitly assumed that AO or conventional 
risk classification will be replaced rather than combined. 
Reed et  al. (2009) cross-classified patients by clinico-
pathologic characteristics from AO and ODX. However, 
they assumed that in the absence of ODX test results, all 
patients with intermediate and high risk according to AO 
receive chemotherapy. They did not report test-treatment 
scenarios where only specific risk groups receive ODX. 
They estimated an ICER of USD10,788/QALY for an 
ODX guided therapy as compared to non ODX guided 
from a US societal perspective. With respect to the Cana-
dian results of the THETA Collaborative, our findings 
are similar. They identified strategy NYY and YYY to 
be cost-effectiveness frontier with ICERs a little higher 
than those for Austria. In addition, in the Canadian set-
ting, strategy NNY is cost effective. The cost-effective-
ness frontier showed a similar shape with a slight shift 
right/up for Austria due to a little higher cost and higher 
QALYs. This can in part be the result of similar sources of 
utility data and probabilities of distant recurrence. How-
ever, countries differ with respect to chemotherapies that 
are provided. In addition, for Austria we did not consider 
end of life care and assumptions of chemotherapy toxici-
ties differ. Hence, it was also found that the strategy NNY 
is cost effective in the analysis of the THETA collabora-
tive but not for Austria.
Our model has several limitations. Though model 
parameters were carefully selected, some information 
was not available for Austria. Therefore, we adapted the 
distribution of the AO risk groups, utility parameters and 
estimates for the risk of distant recurrence from interna-
tional studies (Lo et al. 2010; Paulden et al. 2013; Lidgren 
et al. 2007). Furthermore, since the 21-gene assay is not 
available in Austria, the treatment pattern was assumed 
based on the results of both risk scores as adapted from 
(Lo et  al. 2010) with Austrian experts (Medical Univer-
sity Innsbruck 2012). In general, a review by Carlson and 
Roth (2013) concluded that there are a lack of studies 
reporting the impact of ODX on adjuvant chemotherapy 
use versus a standard approach. Individual health consid-
erations and preferences may be more important in deci-
sions about use of chemotherapy than the results of the 
21-gene assay.
There is evidence that ODX results are associated with 
locoregional recurrence (Mamounas et al. 2010). Within 
our model, we did not consider the risk of local recur-
rence. Due to a lack of more detailed data, treatment 
of distant recurrence was assumed to be similar for all 
patients independent of the patient history. However, our 
microsimulation provides the flexibility to incorporate 
further personalized treatment decisions once that data 
become available.
ODX, as molecular signatures for ER-positive breast 
cancer show convincing analytical validity and clinical 
validity results. However, results have not yet proven 
robust clinical utility. In some cases, where this deci-
sion is difficult, ODX may be used in conjunction with all 
clinicopathological factors to inform treatment decisions 
(Azim et  al. 2013; Senkus et  al. 2013). However, future 
results from large phase III prospective clinical trials 
(TAILORx, RxPONDER) may confirm the accurate use 
of these new tools. Once further data are available, the 
model will be updated accordingly.
Further tests such as EndoPredict, Breast Cancer 
Index, MammaPrint, and Genomic Grade Index have 
shown promising results in ongoing trials. These tests dif-
fer slightly with respect to indication, whether they are 
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prognostic or predictive, whether they must be conducted 
in a central lab, reference lab, or by local pathologists, 
technique (e.g., qRT-PCR, DNA micro array) outcomes 
and risk categories. Most tests require formalin-fixed, par-
affin embedded tissue (Sinn et al. 2013). The EGAPP work-
ing group (EWG) launched by the CDC Office of Public 
Health Genomics in 2009 (EGAPP Working Group 2009) 
concluded that the evidence for the use of a gene expres-
sion profile is insufficient to assess the balance of benefits 
and harms for its proposed uses. The EWG encourages 
further evaluation of these technologies. Likewise, the 
IMPAKT 2012 Working Group suggested “a need to 
develop models that integrate clinicopathological factors 
along with clinical test” (Azim et al. 2013). In addition, Prat 
et al. (2012) created a dataset of 1380 patients to research 
the combination of PAM50, ODX, Mammaprint and SET. 
They showed that combinations of these signatures signifi-
cantly increase prediction performance. Hence, for future 
cost-effectiveness studies, comparators and combinations 
must be thoroughly extended and selected.
Our model can support clinicians in their decision 
making as to whether the relatively small absolute benefit 
of chemotherapy in node-negative, ER-positive women 
outweighs the harm of adverse drug effects. Our discrete 
event simulation model produced useful results, and is 
available to be adapted for rapid assessment of new tests, 
variations in treatment strategies and additional bio-
markers and treatments as they become available.
Conclusion
Our study suggests that ODX applied in all risk groups is 
the most effective strategy. Also the 21-gene assay is cost 
effective for patients independent of the AO risk score 
(Strategy YYY) (ICER 15,700 EUR/QALY) and in patients 
with a high or intermediate AO risk score (strategy NYY) 
(ICER 1600 EUR/QALY). Further research is needed to 
validate the 21-gene assay and use of AO in large pro-
spective studies as well as real world registry studies. The 
results of future studies of other genetic tests may require 
alternative or additional test-treatment strategies.
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